Page 2 - Per Plotnikof News Today

08 February 2024 ALK’s Board of Directors has approved the company’s 2023 annual report. Following a robust performance in Q4, full-year results were in line with the latest outlook. ALK expects...

08 February 2024ALK’s (ALKB:DC / OMX: ALK B / AKBLF) Board of Directors has approved the company’s 2023 annual report. Following a robust performa...

ALK today announced that the European regulatory filing for ACARIZAX® in young children has been accepted for review by the relevant health authorities via a type II variation. The European...

The trial now progresses into its second part, expected to complete later in 2024. ALK to submit a protocol amendment for Phase 1-2 efficacy trial extension. ALK announced today that it has...

The trial now progresses into its second part, expected to complete later in 2024. ALK to submit a protocol amendment for Phase 1-2 efficacy trial...

18.01.2024 - The trial now progresses into its second part, expected to complete later in 2024. ALK to submit a protocol amendment for Phase 1-2 efficacy trial extension. ALK (ALKB:DC / OMX: ALK B / AKBLF) announced today that it has completed the first part of ...

  2024 financial calendar for ALK (ALKB:DC / OMX: ALK B / AKBLF): 11 January 2024: Silent period        8 February 2024: Annual report 2023   ...

ALK and its Japanese partner Torii Pharmaceutical Co., Ltd. today announced that they have expanded their collaboration and entered into an additional license agreement, granting Torii exclusive...

On Wednesday, 15 November 2023 ALK releases its nine-month interim report 2023. ALK will host a meeting for analysts and institutional investors that day at 1.30pm at which Management will review...

ALK delivers 11% revenue growth with operating profit up 120% in Q2 (unaudited) ALK’s revenue grew by 11% in Q2 2023, driven...